SM
ALXN

SG3 Management’s Alexion Pharmaceuticals ALXN Stock Holding History

SG3 Management’s Portfolio ALXN Stock Details ALXN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-6,000
Closed -$937K – 1584
2020
Q4 		$937K Buy
+6,000
New +$771K 0.02% 580

Other funds holding ALXN

BCI
Brinker Capital Investments Berwyn, Pennsylvania $11.7B AUM 21.33% 1-Year Est. Return
NICM
Neo Ivy Capital Management New York $379M AUM 28.34% 1-Year Est. Return
TAIM
TD Ameritrade Investment Management Omaha, Nebraska $9.4B AUM 7.2% 1-Year Est. Return
Barclays
Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return
RG
Retirement Group San Diego, California $279M AUM 22.21% 1-Year Est. Return
CFO
CVA Family Office Denver, Colorado $950M AUM 20.72% 1-Year Est. Return
MAM
Meeder Asset Management Dublin, Ohio $1.75B AUM 34.85% 1-Year Est. Return

SG3 Management's ALXN Position: Q3 2021 in Review

SG3 Management sold out of Alexion Pharmaceuticals (ALXN) in Q3 2021, closing a stake of 3,000 shares — an estimated $551K sold.

SG3 Management first reported a position in ALXN in Q2 2020 and held it in 4 quarters. The position peaked at $4.73M in Q4 2020. 7 funds tracked by Wall St. Rank hold ALXN as of Q3 2021.

  • SG3 Management reported no remaining Alexion Pharmaceuticals position as of Q3 2021 after selling out during the quarter.
  • SG3 Management sold 3,000 Alexion Pharmaceuticals shares in Q3 2021, an estimated $551K.
  • SG3 Management first reported a position in Alexion Pharmaceuticals in Q2 2020 and held it in 4 quarters.
  • SG3 Management's Alexion Pharmaceuticals position peaked at $4.73M in Q4 2020.
  • 7 funds tracked by Wall St. Rank held Alexion Pharmaceuticals as of Q3 2021.

Based on SG3 Management's 13F filing for Q3 2021, filed 15 Nov 2021.